Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

15.48USD
17 May 2019
Change (% chg)

$-0.02 (-0.13%)
Prev Close
$15.50
Open
$15.42
Day's High
$16.46
Day's Low
$15.11
Volume
663,152
Avg. Vol
357,837
52-wk High
$16.46
52-wk Low
$2.76

Latest Key Developments (Source: Significant Developments)

Zynerba Pharmaceuticals Q1 Loss Per Share $0.47
Wednesday, 8 May 2019 

Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS WERE $68.3 MILLION, COMPARED TO $59.8 MILLION AS OF DECEMBER 31, 2018.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS BEYOND EXPECTED NDA SUBMISSION.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO Q1 OF 2021.  Full Article

Zynerba Pharmaceuticals Receives Fast Track Designation For Zygel
Monday, 6 May 2019 

May 6 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FOR ZYGEL™ FOR THE TREATMENT OF BEHAVIORAL SYMPTOMS ASSOCIATED WITH FRAGILE X SYNDROME (FXS).ZYNERBA PHARMACEUTICALS - ENROLLMENT PROGRESSING IN PIVOTAL CONNECT-FX TRIAL OF ZYGEL IN FXS, WITH DATA EXPECTED IN SECOND HALF OF 2019.  Full Article

Scynexis Net Loss For 2018 Was $12.5 Mln Or $0.28 Per Share
Thursday, 14 Mar 2019 

March 14 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.SCYNEXIS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $44.2 MILLION AS OF DECEMBER 31, 2018.SCYNEXIS INC - NET LOSS FOR 2018 WAS $12.5 MILLION, OR $0.28 PER SHARE.  Full Article

Zynerba Pharmaceuticals Says Co Delaying Phase 2B Of ZYN002 In Adult Refractory Focal Epilepsy Until After Readout Of Four Childhood Neuropsych Studies
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS INC - WELL CAPITALIZED WITH CASH RUNWAY EXPECTED INTO SECOND HALF OF 2020 - SEC FILING.ZYNERBA PHARMACEUTICALS - DELAYING PHASE 2B OF ZYN002 IN ADULT REFRACTORY FOCAL EPILEPSY UNTIL AFTER READOUT OF FOUR CHILDHOOD NEUROPSYCH STUDIES.  Full Article

Zynerba Pharmaceuticals Provides Clinical Update And Announces Two New Clinical Indications
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES CLINICAL UPDATE AND ANNOUNCES TWO NEW CLINICAL INDICATIONS.ZYNERBA PHARMACEUTICALS INC - CASH RUNWAY NOW EXTENDS INTO SECOND HALF OF 2020.ZYNERBA - COMPANY WILL FOCUS ON FOUR CHILDHOOD NEUROPSYCHIATRIC DISORDERS: FXS, DEE, AUTISM SPECTRUM DISORDER AND 22Q11.2 DELETION SYNDROME.ZYNERBA PHARMACEUTICALS - POSTPONED INITIATION OF CLINICAL TRIAL IN ADULT EPILEPSY UNTIL AFTER COMPLETION OF FOUR CHILDHOOD NEUROPSYCHIATRIC STUDIES.ZYNERBA PHARMACEUTICALS INC - FRAGILE X SYNDROME PIVOTAL DATA EXPECTED IN 2H2019.ZYNERBA PHARMACEUTICALS - REMAINS ON TRACK TO REPORT TOP LINE RESULTS FROM CONNECT-FX (CLINICAL STUDY OF CANNABIDIOL (CBD) IN CHILDREN IN H2 2019.ZYNERBA - ADDITION OF NEW CHILDHOOD NEUROPSYCHIATRIC CLINICAL TARGETS FOR ZYN002; AUTISM SPECTRUM DISORDER & 22Q11.2 DELETION SYNDROME.ZYNERBA - EXPECTS TO INITIATE OPEN LABEL PHASE 2 STUDIES IN HI 2019, REPORT TOP-LINE RESULTS IN H1 2020 FOR NEW CLINICAL INDICATIONS.  Full Article

Zynerba Pharma Q3 Loss Per Share $0.47
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q3 LOSS PER SHARE $0.47.Q3 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share
Tuesday, 8 May 2018 

May 8 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.ZYNERBA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.91.ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $52.1 MILLION AS OF MARCH 31, IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO 2019.  Full Article

Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60
Monday, 12 Mar 2018 

March 12 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q4 LOSS PER SHARE $0.60.Q4 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.‍EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS​.ZYNERBA PHARMACEUTICALS - BELIEVES ‍CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019​.ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019.  Full Article

Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing
Monday, 5 Mar 2018 

March 5 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING.ZYNERBA - EXPECTS TO INITIATE SINGLE PIVOTAL STUDY MID-YEAR 2018 TO SUPPORT NDA FOR ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS SAYS FDA & CO ARE IN AGREEMENT OVER PRIMARY & KEY SECONDARY ENDPOINTS FOR ZYN002 IN FRAGILE X SYNDROME.  Full Article

Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE.ZYNERBA PHARMACEUTICALS INC - ‍PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018​.ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS​.ZYNERBA - ‍IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES​.ZYNERBA PHARMACEUTICALS INC - ‍PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019​.  Full Article